^
    Back
    Association details:
    Biomarker:NF2 mutation
    Cancer:Breast Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Ann Oncol
    Title:

    Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer

    Excerpt:
    Patients with mesenchymal/MpBC treated with temsirolimus-based regimens were evaluated...Of the eight patients who achieved SD ≥6 months/CR/PR, all 4 patients with available tissue had a molecular aberration that activate the PIK3CA/Akt/mTOR axis: PIK3CA mutation = 2; PTEN loss = 1; NF2 aberration = 1.
    Secondary therapy:
    temsirolimus + pegylated liposomal doxorubicin
    DOI:
    10.1093/annonc/mdv163